Abstract
Background: Clinical evidence regarding intestinal Behçet's disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods: An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results: Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions: In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 156-162 |
| Number of pages | 7 |
| Journal | Journal of Gastroenterology |
| Volume | 49 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 Jan |
Fingerprint
Keywords
- Anti-TNFα mAb
- Consensus statements
- Intestinal Behçet's disease
ASJC Scopus subject areas
- Gastroenterology
Cite this
The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease : Indication of anti-TNFα monoclonal antibodies. / Hisamatsu, Tadakazu; Ueno, Fumiaki; Matsumoto, Takayuki; Kobayashi, Kiyonori; Koganei, Kazutaka; Kunisaki, Reiko; Hirai, Fumihito; Nagahori, Masakazu; Matsushita, Mitsunobu; Kobayashi, Kenji; Kishimoto, Mitsumasa; Takeno, Mitsuhiro; Tanaka, Masanori; Inoue, Nagamu; Hibi, Toshifumi.
In: Journal of Gastroenterology, Vol. 49, No. 1, 01.2014, p. 156-162.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease
T2 - Indication of anti-TNFα monoclonal antibodies
AU - Hisamatsu, Tadakazu
AU - Ueno, Fumiaki
AU - Matsumoto, Takayuki
AU - Kobayashi, Kiyonori
AU - Koganei, Kazutaka
AU - Kunisaki, Reiko
AU - Hirai, Fumihito
AU - Nagahori, Masakazu
AU - Matsushita, Mitsunobu
AU - Kobayashi, Kenji
AU - Kishimoto, Mitsumasa
AU - Takeno, Mitsuhiro
AU - Tanaka, Masanori
AU - Inoue, Nagamu
AU - Hibi, Toshifumi
PY - 2014/1
Y1 - 2014/1
N2 - Background: Clinical evidence regarding intestinal Behçet's disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods: An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results: Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions: In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.
AB - Background: Clinical evidence regarding intestinal Behçet's disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs. Methods: An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted. Results: Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized. Conclusions: In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.
KW - Anti-TNFα mAb
KW - Consensus statements
KW - Intestinal Behçet's disease
UR - http://www.scopus.com/inward/record.url?scp=84895076984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895076984&partnerID=8YFLogxK
U2 - 10.1007/s00535-013-0872-4
DO - 10.1007/s00535-013-0872-4
M3 - Article
C2 - 23955155
AN - SCOPUS:84895076984
VL - 49
SP - 156
EP - 162
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
SN - 0944-1174
IS - 1
ER -